FDA approves Avid's PET agent for tau pathology imaging

By LabPulse.com staff writers

May 29, 2020 -- In what the agency called a regulatory first, the U.S. Food and Drug Administration (FDA) has approved the radiopharmaceutical flortaucipir F-18 for imaging tau pathology on positron emission tomography (PET) scans. The agent was developed by Eli Lilly subsidiary Avid Radiopharmaceuticals and will be marketed as Tauvid.

Tauvid is indicated for adult patients with cognitive impairment who are being evaluated for Alzheimer's disease. The PET radiopharmaceutical helps clinicians estimate the density and distribution of tau neurofibrillary tangles in the brain, which are a marker of Alzheimer's disease.

In announcing the approval on May 28, the FDA noted that while the agency has previously approved imaging agents for amyloid pathology -- another neuropathological hallmark of Alzheimer's disease -- the Tauvid approval is the first for imaging of tau.

Tau and amyloid are both acknowledged as hallmarks of Alzheimer's disease. In Alzheimer's patients, tau proteins can develop inside neurons in the brain, creating neurofibrillary tangles. After injection, Tauvid binds to locations in the brain that are associated with the misfolding of tau proteins; these locations can then be identified on PET scans.

"This approval will provide healthcare professionals with a new type of brain scan to use in patients being evaluated for Alzheimer's disease," said Dr. Charles Ganley, director of the FDA's Office of Specialty Medicine in the Center for Drug Evaluation and Research.

Tau protein biomarker proves itself in Alzheimer's blood test
Swedish researchers have developed a test for Alzheimer's disease that measures a particular variant of tau protein called p-tau181 in everyday blood...
Evidence builds for Alzheimer's beta-amyloid blood test
Blood-based biomarker testing for Alzheimer's disease performed well in two prospective studies for assessing beta-amyloid plaque buildup in the brain....
FDA announces Beckman Coulter recall of hematology analyzers
Beckman Coulter Life Sciences has recalled several of its hematology analyzers due to the risk of inaccurate results, according to a U.S. Food and Drug...
Blood tau test works as biomarker for deadly Creutzfeldt-Jakob disease
Testing for the tau protein in blood could help predict the outlook for the rare and deadly Creutzfeldt-Jakob disease, a discovery that also has implications...
Cygnus unveils new ELISA kit for gene therapy
Cygnus Technologies has introduced a new enzyme-linked immunosorbent assay (ELISA) test for use with recombinant vaccines and viral vectors in gene therapy...

Copyright © 2020 LabPulse.com

Last Updated ls 5/29/2020 11:21:41 AM